Because new modes of action for the treatment of psoriatic arthritis (PsA) are emerging, it is important to understand the use of switching to a second or third antitumor necrosis factor (anti-TNF) agent. This study investigated drug survival and treatment response rates of patients with PsA undergoing second- and third-line anti-TNF therapy.
|Journal||Journal of Rheumatology|
|Publication status||Published - 2016|
Subject classification (UKÄ)
- Rheumatology and Autoimmunity